J Stolk1, W Broekman2, T Mauad3, J J Zwaginga4, H Roelofs4, W E Fibbe4, J Oostendorp5, I Bajema6, M I M Versteegh7, C Taube2, P S Hiemstra2. 1. From the Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands, j.stolk@lumc.nl. 2. From the Department of Pulmonology, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Pathology, São Paulo University Medical School, São Paulo, Brazil. 4. Department of Immunohaematology and Blood Transfusion. 5. Department of Clinical Pharmacy and Toxicology. 6. Department of Pathology and. 7. Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
BACKGROUND: Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema. AIM: To study the safety and feasibility of bone marrow-derived autologous (BM-) MSC intravenous administration to patients with severe emphysema. DESIGN: A phase I, prospective open-label study registered at ClinicalTrials.gov as NCT01306513 Eligible patients had lung volume reduction surgery (LVRS) on two separate occasions. During the first LVRS bone marrow was collected, from which MSCs were isolated and expanded ex vivo After 8 weeks, patients received two autologous MSC infusions 1 week apart, followed by the second LVRS procedure at 3 weeks after the second BM-MSC infusion. METHODS: Up to 3 weeks after the last MSC infusion adverse events were recorded. Using immunohistochemistry and qPCR for analysis of cell and proliferation markers, emphysematous lung tissue obtained during the first surgery was compared with lung tissue obtained after the second surgical session to assess BM-MSC effects. RESULTS: From 10 included patients three were excluded: two did not receive MSCs due to insufficient MSC culture expansion, and one had no second surgery. No adverse events related to MSC infusions occurred and lung tissue showed no fibrotic responses. After LVRS and MSC infusions alveolar septa showed a 3-fold increased expression of the endothelial marker CD31 (P = 0.016). CONCLUSIONS: Autologous MSC treatment in severe emphysema is feasible and safe. The increase in CD31 expression after LVRS and MSC treatment suggests responsiveness of microvascular endothelial cells in the most severely affected parts of the lung.
BACKGROUND: Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema. AIM: To study the safety and feasibility of bone marrow-derived autologous (BM-) MSC intravenous administration to patients with severe emphysema. DESIGN: A phase I, prospective open-label study registered at ClinicalTrials.gov as NCT01306513 Eligible patients had lung volume reduction surgery (LVRS) on two separate occasions. During the first LVRS bone marrow was collected, from which MSCs were isolated and expanded ex vivo After 8 weeks, patients received two autologous MSC infusions 1 week apart, followed by the second LVRS procedure at 3 weeks after the second BM-MSC infusion. METHODS: Up to 3 weeks after the last MSC infusion adverse events were recorded. Using immunohistochemistry and qPCR for analysis of cell and proliferation markers, emphysematous lung tissue obtained during the first surgery was compared with lung tissue obtained after the second surgical session to assess BM-MSC effects. RESULTS: From 10 included patients three were excluded: two did not receive MSCs due to insufficient MSC culture expansion, and one had no second surgery. No adverse events related to MSC infusions occurred and lung tissue showed no fibrotic responses. After LVRS and MSC infusions alveolar septa showed a 3-fold increased expression of the endothelial marker CD31 (P = 0.016). CONCLUSIONS: Autologous MSC treatment in severe emphysema is feasible and safe. The increase in CD31 expression after LVRS and MSC treatment suggests responsiveness of microvascular endothelial cells in the most severely affected parts of the lung.
Authors: Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes Journal: Gut Date: 2010-10-04 Impact factor: 23.059
Authors: J Stolk; M I M Versteegh; L J Montenij; M E Bakker; E Grebski; M Tutic; S Wildermuth; W Weder; M el Bardiji; J H C Reiber; K F Rabe; E W Russi; B C Stoel Journal: Eur Respir J Date: 2007-03-01 Impact factor: 16.671
Authors: Victor Kim; Dana M Kretschman; Alice L Sternberg; Malcolm M DeCamp; Gerard J Criner Journal: Am J Respir Crit Care Med Date: 2012-08-09 Impact factor: 21.405
Authors: John E McDonough; Ren Yuan; Masaru Suzuki; Nazgol Seyednejad; W Mark Elliott; Pablo G Sanchez; Alexander C Wright; Warren B Gefter; Leslie Litzky; Harvey O Coxson; Peter D Paré; Don D Sin; Richard A Pierce; Jason C Woods; Annette M McWilliams; John R Mayo; Stephen C Lam; Joel D Cooper; James C Hogg Journal: N Engl J Med Date: 2011-10-27 Impact factor: 91.245
Authors: Michael A Thomashow; Daichi Shimbo; Megha A Parikh; Eric A Hoffman; Jens Vogel-Claussen; Katja Hueper; Jessie Fu; Chia-Ying Liu; David A Bluemke; Corey E Ventetuolo; Margaret F Doyle; R Graham Barr Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405
Authors: Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén Journal: Lancet Date: 2008-05-10 Impact factor: 79.321